NanoViricides Inc. (NNVC)

[changes_iv]

What brought me to become an investor in NNVC?

Several years ago, when searching for a good stock to invest on, persuasive arguments flashed across my laptop screen, arguments that really caught my attention and captured my imagination. Demographics, science and Patrick Cox writings, all contributed to my selection of Nanoviricides, Inc.(NNVC) as the company to invest on. As Patrick Cox once wrote, "...Unlike these existing drugs, however, NanoViricides’ technology acts before the virus has had a chance to gain entry into a healthy cell. This is like defeating a besieging enemy army with withering fire before it’s forced the city gates or undermined the defensive walls. The alternative methods used today are the equivalent of a last-ditch house-to-house battle after the defenses have been breached.

These current anti-viral drugs have other drawbacks. They are expensive and resistance develops as the virus mutates. There is also toxicity.

More than 99% of seasonal flu viruses have developed resistance to Tamiflu, according to the CDC. Unlike such drugs, NanoViricides has found no evidence of toxicity or resistance in animal trials. There is no mechanism by which resistance can develop against NanoViricides’ technology. If the surface proteins on the virus mutate away from the ability of the nano-micelle to attach to them, they have also mutated away from the ability to attach to the surface of a human cell. The viruses don’t have a chance. The Viral Equivalent of Penicillin.

These current anti-viral drugs have other drawbacks. They are expensive and resistance develops as the virus mutates. There is also toxicity...".

The Nano-Cides are agnostic to the host, but more than that... ---

---

1)the current/conventional drugs in the marketplace are expensive and resistance develops as the virus mutates
2)conventional drugs toxicity and side effects
3)Nanoviricides, Inc. has had no failures in 5000 animal studies, "...and none are anticipated in humans because we are agnostic to the host...as long as you have a virus in your circulation, we destroy it..." Dr. Eugene Seymour, CEO Nanoviricides, Inc.

Sometime ago, Megawati, Indonesian President said the following in a speech broadcast, "To families of the deceased victims, on behalf of the people and the government, I convey my deepest sorrow. I pray that they may be given the strength and patience in facing this trial," Strength and patience, the exhortation of an powerful authoritarian government, completely helpless to protect its people against an invisible "life-taking" enemy. Today about 2.5 billion people, or 40% of the world’s population, live in areas where there is a risk of dengue transmission. Dengue is endemic in at least 100 countries in Asia, the Pacific, the Americas, Africa, and the Caribbean. The World Health Organization (WHO) estimates that 50 to 100 million infections occur yearly, including 500,000 DHF cases and 22,000 deaths, mostly among children --- Center for Disease Control.

Although NanoViricides has many potential virus targets for its technology, currently it has focused its initial thrust to market with influenza (FluCide™) and Dengue (DengueCide™ ***), major threats in a potential pandemic. DengueCide™ and FluCide™ are now the thrusters to reach the market, to capitalize and make possible the pursuit of other target drugs viable. As we all know, work is being done with NanoViricides’ test drugs at research hospitals, universities and veterinary schools. One of the most recent collaborators in their quest for a healthier world is UCLA School of Medicine. Dr. Seymour explains, "...They have expressed a serious interest in collaborating with us on a number of basic science projects that will yield information that the FDA will require. The amount of time and money that we will save is truly incalculable. Whenever you present a new technology to the FDA, having a prestigious Institute and University behind you is extremely valuable."

We've all heard about priority review vouchers (PRV). They are "...transferrable go-to-the-front-of-the-regulatory-line “chits.” And they are awarded to companies that develop approved drugs for certain orphan diseases. Estimates of the financial value of these chits range from $200 million to well over half a billion dollars. Most drug development companies depend on partnerships with Big Pharma to fund extremely expensive Phase 3 trials that precede drug approval. If a company that won approval for an orphan drug were to be awarded a PRV, however, it would change the entire risk/reward picture. At the very least, it could lead to a much bigger cash payout for the developing company in a Big Pharma drug deal." ~ Patrick Cox. --- http://www.law.harvard.edu/programs/petrie-flom/workshops_conferences/2008_workshops/Grabowski.pdf ---

The efficacy of DengueCide™ *** is unprecedented ~ Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley.

The time from Phase II to market is often shorter for orphan drugs due to shorter and smaller clinical trials and FDA Fast Track designation.

Once a compound has been granted orphan designation, the odds for approval are high (82%) compared to traditional drugs (35%).

I believe the people of Nanoviricides and their collaborators are God sent. Where there is knowledge, inspiration and the will, there is a way. We, as a nation, are currently "...Billions of dollars of stress on personal savings, Social Security, and Medicare each year. And the “cost” of illness — both in dollars and pain — only grows with age…" ~ Patrick Cox. Nanoviricides could very well be the company that greatly reduces, if not eliminate, many of those problems. It could cure any virus, from warts and herpes to Ebola and AIDS.

After DengueCide™, and FluCide™ more Cides will be guided, positioned, to take their own "controlled" track to market. HIVCide-I could very well be next in taking another track to market as "functional cure" for HIV/AIDS which alone represents a potential $21 billion market ---

---. I can almost see success in human trials for DengueCide™ and FluCide™ and the people afflicted with HIV/AIDS writing, clamoring for the HIVCide-I.

Static equilibrium of Nanoviricides will be favorably upset by management timely directives that will quickly convert Nanoviricides, currently a multi-million dollar cap company, into one with a multi-Billion dollar cap. Nanoviricides has management, "ball players" that will not remain "ghosts" for much longer. ---

--- Nanoviricides, a pioneering company in advanced bionanotechnology, has the money to take it through Phase I/II which should start on 3Q 2014! Anticipation will build up as we approach human trials moving the nav of NNVC higher.

We are not headed to "a field of dreams" in IOWA. ---

--- We are headed for the complete integration of the cGMP pilot plant in Shelton, CT on 4Q 2013. That is very soon, this year. Immediately after integration, the cGMP pilot plant will be commissioned, soon thereafter it will be lit, ready, validated and many investors will come. Nanoviricdes is a company on the cutting edge of bionanotechnology, at the edge of a new frontier in a nanoscopic universe. The question with this company is not if but when will it take off in a steep climb. There is no doubt in my mind that the climb "home" and in share price "new highs", begins this year, 2013.

Shelton, CT is a brief stop on our way home, home, a place where "...Surely sorrows shall find their end and all our troubles will be gone..." ---

---. Home is a place for a more perfect people, a more perfect nation leading to a more perfect world, with greater freedom from disease, with greater freedom from want. As a former U.S. President once put it, "...and after all, why shouldn't we believe that?, we are Americans..." Believe! That is the American Spirit, the Spirit of ALL freedom-loving people in the common pursuit of their dreams.
=================================================================
*** DengueCide™ awaits approval of their Orphan Drug designation application to FDA, Aug 2013